Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Relutrigine treats developmental and epileptic encephalopathies, which have an extremely high mortality rate due to seizure burden.
read more
Tinlarebant reduced lesion growth compared to placebo, marking the first therapeutic candidate to demonstrate clinical efficacy for STGD1.
read more
Lupin will partner with two global private equity firms to acquire Vitabiotics in a deal that could be worth $1.25 billion.
read more
The orally bioavailable small molecule targets protein misfolding to attack the root cause of the disease rather than treating the resulting symptoms.
read more
The cuts will be made by the end of 2027 at Novartis' plant in Stein, as the company updates its production capabilities.
read more
An analysis of two long shot phase 3 trials found no delay in Alzheimer’s disease progression.
read more
The trial is the first successfully completed phase 3 study of a Factor XIa inhibitor.
read more
A scheduled review found that the oral medication was unlikely to meet its primary endpoint in a phase 3 trial.
read more
Halda's technology platform is capable of developing next-gen oral drugs to treat tumors in breast, lung and prostate cancers.
read more
The rating places the global packaging solutions supplier in the top 5% of companies for sustainability performance.
read more
The treatment was shown to be statistically non-inferior to multi-tablet regimens, with potential benefits of a lower pill burden and better adherence.
read more
Metsera announced that it has entered into an amended merger agreement with Pfizer in a deal now worth up to $10 billion.
read more
Fenebrutinib showed positive results for both relapsing and primary progressive multiple sclerosis, making it the first potential BTK inhibitor for MS.
read more
When taken in combination with an oral antidepressant, Caplyta was shown to have superior efficacy and a favorable safety profile.
read more
As a result, the company is currently restructuring to reduce its annual direct R&D spend by 60%.
read more